All In Biotech

Drug Trial Radar · NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

453

Planned (sponsor's estimate)

Start

Apr 17, 2018

Primary completion

Apr 20, 2028

Study completion Jul 7, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding. The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Conditions

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Small Cell Lung Cancer (SCLC)
  • Follicular Lymphoma (FL)

Interventions

  • Mevrometostat (PF-06821497)Drug

    Oral continuous

  • EnzalutamideDrug

    Oral continuous

  • ItraconazoleDrug

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)Time frame: Baseline up to 90 days
  2. Overall safety profile including adverse eventsTime frame: Baseline up to approximately 2 years
  3. Preliminary efficacy determination as evaluated by disease specific response criteriaTime frame: Through study completion, approximately 2 years past last patient first visit.
  4. Overall safety profile including laboratory abnormalitiesTime frame: Baseline up to approximately 2 years
  5. Overall safety profile including vital signsTime frame: Baseline up to approximately 2 years
  6. Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survivalTime frame: Baseline until disease progression or death or through study completion (approx 2 years)

Locations

84 sites in 8 countries. Site status is shown where the registry gives one.

  • Banner-University Medical Center Tucson

    Tucson, Arizona · Active not recruiting

  • The University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Active not recruiting

  • The University of Arizona Cancer Center

    Tucson, Arizona · Active not recruiting

  • Arizona Urology Specialists, PLLC

    Tucson, Arizona · Terminated

  • Pacific Cancer Medical Center INC

    Anaheim, California · Active not recruiting

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Active not recruiting

  • City of Hope Investigational Drug Services (IDS)

    Duarte, California · Active not recruiting

  • Norwalk Hospital

    Norwalk, Connecticut · Active not recruiting

  • The University of Kansas Cancer Center, Investigational Drug Services

    Fairway, Kansas · Active not recruiting

  • The University of Kansas Clinical Research Center

    Fairway, Kansas · Active not recruiting

  • The University of Kansas Hospital

    Kansas City, Kansas · Active not recruiting

  • The University of Kansas Medical Center Medical Office Building

    Kansas City, Kansas · Active not recruiting

  • The University of Kansas Cancer Center - Indian Creek Campus

    Overland Park, Kansas · Active not recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Active not recruiting

  • Norton Cancer Institute - Downtown

    Louisville, Kentucky · Active not recruiting

  • Norton Cancer Institute, Norton Healthcare Pavilion

    Louisville, Kentucky · Active not recruiting

  • Norton Hospital

    Louisville, Kentucky · Active not recruiting

  • Maryland Oncology Hematology, P.A.

    Rockville, Maryland · Terminated

  • Brigham and Women's Hospital

    Boston, Massachusetts · Active not recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • Dana Farber Cancer Institute- Chestnut Hill

    Newton, Massachusetts · Active not recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Active not recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Active not recruiting

  • OU Health University of Oklahoma Medical Center

    Oklahoma City, Oklahoma · Recruiting

  • Stephenson Cancer Center (chemo location)

    Oklahoma City, Oklahoma · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Parkway Surgery Center

    Myrtle Beach, South Carolina · Recruiting

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Austin Midtown

    Austin, Texas · Terminated

  • University of Texas Southwestern Medical Center - Simmons Cancer Center

    Dallas, Texas · Active not recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Active not recruiting

  • UT Southwestern University Hospital - William P. Clements, Jr

    Dallas, Texas · Active not recruiting

  • UT Southwestern University Hospital - Zale Lipshy

    Dallas, Texas · Active not recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • US Oncology Investigational Product Center (IPC)

    Irving, Texas · Terminated

  • US Oncology Investigational Products Center

    Irving, Texas · Terminated

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Active not recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.